ITM Receives FDA Complete Response Letter for ITM-11
Garching/Munich, Germany and Princeton, New Jersey, August 10, 2026 ITM Isotope Technologies Munich SE (ITM) announced that the U.S....
Radiopharmaceutical Therapy
Advertisement
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Telix ProstACT Phase 3 Study Shows Positive Safety Results
Melbourne, Australia & Indianapolis, United States – March 10, 2026 Telix Pharmaceuticals has announced that Part 1 of the...
ITM Highlights Phase 3 NET Trial Data at ENETS 2026
February 25, 2026 – Garching / Munich, Germany ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotechnology company, has...
Advertisement
